Roche signs major ADC licensing deal with China's Hansoh Pharma

Roche has entered a significant licensing agreement with Hansoh Pharmaceutical Group to develop a portfolio of antibody-drug conjugates, continuing its strategy of sourcing innovative drugs from China. The deal underscores the growing importance of Chinese biotech in global pharma pipelines, though financial terms and specific targets remain undisclosed. This is a notable corporate transaction that could impact Roche's pipeline and the broader biotech sector.